Negative in Ames, in vitro mouse lymphoma TK and in vivo rat micronucleus assays
“Brensocatib was found to be negative for genotoxic potential in the in vitro bacterial reverse mutation (Ames) assay, an in vitro mouse lymphoma cell thymidine kinase locus assay, and in vivo micronucleus assay in rats.”
104-week rat and 6-month Tg rasH2 mouse: no neoplastic findings (>50x and >60x MRHD unbound AUC)
“No neoplastic findings were observed in a 6-month Tg Ras mouse study and a 104-week carcinogenicity study in rats up to the highest doses tested yielding AUC-based (unbound brensocatib fraction) safety margins of > 60-fold (mice) and > 50-fold (rat) to the MRHD.”
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Rat EFD: bent scapula malformation at 100 mg/kg/day (3.7% of fetuses)
“Drug-related adverse skeletal malformation of bent scapula was observed in fetuses from pregnant dams administered 100 mg/kg/day brensocatib (4 of 110 fetuses, 3.7%).”
No CNS or respiratory effects in rats at oral doses up to 200 mg/kg
“Safety pharmacology studies indicated that brensocatib did not affect the central nervous system or respiratory system in Han Wistar rats at oral doses up to 200 mg/kg”
“Brensocatib was found to be negative for genotoxic potential in the in vitro bacterial reverse mutation (Ames) assay, an in vitro mouse lymphoma cell thymidine kinase locus assay, and in vivo micronucleus assay in rats.”
“Brensocatib was found to be negative for genotoxic potential in the in vitro bacterial reverse mutation (Ames) assay, an in vitro mouse lymphoma cell thymidine kinase locus assay, and in vivo micronucleus assay in rats.”
“Brensocatib was found to be negative for genotoxic potential in the in vitro bacterial reverse mutation (Ames) assay, an in vitro mouse lymphoma cell thymidine kinase locus assay, and in vivo micronucleus assay in rats.”
hERG IC50 13.9 uM; 176-fold margin to free Cmax at MRHD (25 mg QD); low arrhythmogenic risk
“Brensocatib blocked the hERG-encoded potassium channel with an IC50 of 13.9 μM. The exposure margin to the free exposure (Cmax) at steady state of 0.079 µM (total Cmax = 0.616 µM or 259 ng/mL) in humans at MRHD (25 mg QD) is 176-fold, indicating a low arrhythmogenic risk.”
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative